medwireNews: ESMO’s Clinical Practice Guideline for the management of metastatic breast cancer is now available and published in the Annals of Oncology.
The guideline was developed by a panel of 28 international experts in accordance with ESMO’s standard operating procedure and replace the previous reference document, the 5th ESO–ESMO international consensus guidelines for advanced breast cancer.
The recommendations are based on available evidence and expert opinion, and cover all aspects of metastatic breast cancer care, including diagnosis, staging, risk assessment, treatment, disease monitoring, and palliative care.
Giuseppe Curigliano, Chair of the ESMO Guidelines Committee, noted in a press release that the document is “designed to integrate even the most recent, potentially practice-changing data by providing graded recommendations for different treatment choices according to the levels of evidence available to support them, based on their rating within the ESMO Magnitude of Clinical Benefit Scale and the ESMO Scale for the Clinical Actionability of Molecular Targets.”
The guideline authors also emphasize the importance of a multidisciplinary approach for optimal management of patients, and state: “These guidelines are based on breast cancer biological subtypes even though modern targeted drugs may lead to revisions of these subtypes in the future, as exemplified by the first tumour-agnostic approvals.”
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group